VANCOUVER, Wash., Jan. 8, 2025 (GLOBE NEWSWIRE) — Absi Corporation (NASDAQ: ABSI), a data-first generative AI drug discovery company, today announced that AMD Instinct™ Accelerator and ROCm™ announced a strategic alliance with Software that powers critical AI drug discovery workloads, including Absci’s advanced de novo antibody design models. AMD will also make a $20 million investment in Absci, structured as a private investment in public equity (PIPE), supporting the growing demand for innovative AI applications in drug discovery.
This strategic partnership will deliver better biologics for patients by delivering an AI solution optimized for complex biological modeling that delivers superior performance, reduced infrastructure costs, and faster innovation cycles. Support Absci’s mission to create faster. Absci Founder and CEO Sean McClain will discuss strategic partnerships at the 43rd Annual JPMorgan Healthcare Conference on Wednesday, January 15th at 4:30pm PT. Absci and AMD showcase the outstanding performance of AMD’s Instinct accelerator in addressing complex biological applications, including Absci’s proprietary IgDesign1 model, the first in vitro validated reverse folding model for antibody design .
Sean McClain, founder and CEO of Absci, said: “This partnership with AMD gives us the unique advantage of working closely with a partner who is passionate about supporting our needs while delivering the most efficient and innovative AI solutions. AMD’s high-performance computing will enable us to further develop the next generation. We are excited about the potential of this partnership to accelerate the future of drug discovery. I’m excited.”
Mark Papermaster, Executive Vice President and Chief Technology Officer of AMD, said: “We are proud to partner with Absci, a company at the forefront of AI-driven drug discovery, to further accelerate therapeutic breakthroughs and transform the way biologics are developed.” I am. . “Absci’s groundbreaking work in AI drug discovery is a perfect fit for AMD’s high-performance computing solutions and software designed for the most demanding AI workloads.”
About Absea
Absci is a data-first, generative AI drug discovery company that combines AI and scalable wet lab technology to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase probability of success by simultaneously optimizing multiple drug properties critical to both development and therapeutic efficacy. With data trained, AI-authored, and wet-lab validated, billions of cells can be screened weekly, moving from AI-designed to wet-lab-validated candidates in just 6 weeks. can. Absci’s headquarters are in Vancouver, Washington, with an AI research lab in New York City and an innovation center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
About AMD
For more than 50 years, AMD has been driving innovation in high-performance computing, graphics, and visualization technologies. Billions of people around the world, leading Fortune 500 companies, and cutting-edge scientific research institutions rely on AMD technology every day to improve the way they live, work, and play. AMD employees are focused on building high-performing, adaptive products that push the limits of what’s possible and provide leadership. To learn more about how AMD enables today and inspires tomorrow, visit the AMD (NASDAQ: AMD) website, blog, LinkedIn, and X-Page.
Absci’s forward-looking statements
Certain statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act. It is considered. Revised 1934 edition. Includes statements containing the words “will,” “may,” “seeks,” “anticipates,” and “plans.” “believe,” “aim,” “may,” “anticipate,” “estimate,” “extend,” “expect,” “intend” or similar expressions. Absci is committed to accelerating the future of AI drug discovery, Absci’s leadership in AI drug discovery, Absci’s ability to leverage AMD’s equity investment, and Absci’s ability to create better biologics and develop the next generation of antibodies. These forward-looking statements are intended to be forward-looking statements, including statements that may be forward-looking or implied. Therapeutic products are subject to the forward-looking safe harbor provisions contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. and Absci makes this statement for the purpose of complying with these safe harbor provisions. These forward-looking statements reflect Abshi’s current beliefs regarding its plans, intentions, expectations, strategies and prospects and are based on currently available information and Abshi’s assumptions. Absci cannot give any assurance that any plans, intentions, expectations or strategies will be realized or achieved. In addition, actual results may differ materially from those described in the forward-looking statements and are subject to various risks and factors. Something beyond Absci’s control. These include risks and uncertainties relating to Absci’s ability to leverage AMD’s investments, effective collaboration in research, drug discovery and development activities with partners or potential partners, and Absci’s dependence; , but not limited to. the ability and ability of third parties, existing and potential partners to support our internal development programs to pursue the development and commercialization of our product candidates or product candidates, including the manufacturing and supply of preclinical and clinical supplies of our product candidates or their components; Willingness. the terms of Absci’s partnership agreements, general market conditions and regulatory developments that may affect Absci’s and its partners’ activities under these agreements, and Absci’s most recent periodic filings with U.S. securities exchanges; As well as the risks described in this report, we also discuss potential risks, uncertainties and other important factors in subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, Absci undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Absci Investor Contact
Alex Khan
Vice President of Finance and Investor Relations
investor@absci.com
Absimedia contact information
press@absci.com
Investor information:
matt ramsay
AMD Investor Information
Matthew.Ramsay@amd.com
AMD Media Contact Information
Brandi Martina
AMD Communications
brandi.martina@amd.com
